ID
16701
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Long-Term Follow-Up Assessment
Lien
https://clinicaltrials.gov/ct2/show/NCT00373425
Mots-clés
Versions (1)
- 01/08/2016 01/08/2016 -
Téléchargé le
1 août 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Long-Term Follow-Up Assessment, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Long-Term Follow-Up Assessment, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
Radiology
Description
Chest/upper abdomen CT scan
Type de données
integer
Alias
- UMLS CUI [1]
- C0202823
- UMLS CUI [2]
- C1627748
Description
Date chest/upper abdomen CT scan
Type de données
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0202823
- UMLS CUI [2,1]
- C0011008
- UMLS CUI [2,2]
- C1627748
Description
If relapse was documented, complete Relapse Report and New Lesion Specification page.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0277556
Description
Radiologic Examination
Type de données
boolean
Alias
- UMLS CUI [1]
- C0043299
Description
Date of assessment
Type de données
date
Alias
- UMLS CUI [1]
- C2985720
Description
Evaluation Method
Type de données
text
Alias
- UMLS CUI [1]
- C2911685
Description
If relapse was documented, complete Relapse Report and New Lesion Specification page.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0277556
Description
Chest X-ray
Type de données
boolean
Alias
- UMLS CUI [1]
- C0039985
Description
Chest CT
Type de données
boolean
Alias
- UMLS CUI [1]
- C0202823
Description
CT of the chest/upper abdomen
Type de données
boolean
Alias
- UMLS CUI [1]
- C0202823
- UMLS CUI [2]
- C1627748
Description
Long-Term Follow-Up Adverse Events
Description
Long-Term Follow-Up Adverse Events
Description
Record only study drug-related events that are ongoing or new.
Type de données
text
Alias
- UMLS CUI [1]
- C0877248
Description
Grade severity (1,2,3,4,5) using NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. A change in CTC grade should be recorded as a separate event.
Type de données
integer
Alias
- UMLS CUI [1]
- C1710066
Description
Adverse Event Start Date
Type de données
date
Alias
- UMLS CUI [1]
- C2697888
Description
Adverse Event End Date
Type de données
date
Alias
- UMLS CUI [1]
- C2697886
Description
If event is serious, complete the SERIOUS ADVERSE EVENT FORM and fax to the appropriate number on the CRF General lnstructions page.
Type de données
boolean
Alias
- UMLS CUI [1]
- C1710056
Similar models
Long-Term Follow-Up Assessment, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0750480 (UMLS CUI [1,2])
C1522577 (UMLS CUI [1,2])
C0007131 (UMLS CUI [1,2])
C1627748 (UMLS CUI [2])
C0202823 (UMLS CUI [1,2])
C0011008 (UMLS CUI [2,1])
C1627748 (UMLS CUI [2,2])
C1627748 (UMLS CUI [2])